Mechanisms of cellular response to oxidative stress, drug and carcinogen metabolism, pharmacokinetics assay development, mass spectrometry, HPLC. Dr. Henderson is pursuing the development of advanced diagnostics with the goal of predicting patient response to cancer drugs prior to initiation of toxic chemotherapy. The diagnostics development is enabled by accelerator mass spectrometry (AMS), an ultrasensitive technology for detecting rare isotopes such as radiocarbon and tritium in biological samples. AMS is also useful for measuring pharmacokinetics of small drug doses in humans, which Dr. Henderson is applying to drug development and drug formulation studies. Another project involves the incorporation of hydrophobic drugs and membrane proteins into nanoparticles made of apolipoproteins and phospholipids called nanolipoproitein particles (NLPs). NLPs closely mimic the cellular membrane bilayer, and render hydrophobic molecules water soluble. Dr. Henderson is using NLPs for drug delivery and protein biochemistry studies that are related to breast cancer research.
Hematology and Oncology
Ph.D., Georgia Institute of Technology, Atlanta, Georgia, 1999
B.S., University of Florida, Gainesville, Florida, 1992
American Association for Advancement of Science
American Association for Cancer Research
American Chemical Society
Environmental Mutagen Society
Select Recent Publications
For a comprehensive list of Dr. Henderson's publications, please click here (opens new window).